Next-Generation Sequencing: Will It Really Replace Single-Gene Tests in Pathology Labs?
We asked oncology care teams from both sides of Atlantic Ocean whether – and why – they are implementing NGS in routine biomarker testing
sponsored by Thermo Fisher Scientific
“Like many in the field of cancer diagnostics, we’re starting to substitute next-generation sequencing for a lot of our traditional tests,” says Matt Hiemenz, Assistant Director of the Clinical Genomics Laboratory at Children’s Hospital of Los Angeles (CHLA). It’s a shift well worth making, he continues. “With NGS, you can multiplex hundreds of different fusions in a single test. That’s incredibly helpful in terms of diagnosing challenging lesions and maximizing your chances of finding a useful prognostic indicator or treatment target.”
Hiemenz is not the only laboratory medical professional making the move. Tabetha Sundin, Molecular Diagnostics and Serology Scientific Director at Sentara Healthcare, says, “We moved to NGS for non-small cell lung carcinoma testing, which allowed us to bring many of the single-gene tests together. Now, we can look at DNA mutations and structural variance, such as copy number variance and fusions, all in one assay. That saves us time, tissue, and cost.”
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.